Jagsonpal Pharmaceuticals Share Price Targets
Jagsonpal Pharmaceuticals Limited | |||
 | Price: ₹253.10 (-6.18%) | ||
| 52 Week Low: ₹137.76 52 Week High: ₹328.04 | |||
| Market Capital: 1,489.2 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Jagsonpal Pharmaceuticals Stock Comparison: Jagsonpal Pharmaceuticals vs Bliss GVS Pharma | Jagsonpal Pharmaceuticals vs Lincoln Pharmaceuticals | Jagsonpal Pharmaceuticals vs Bajaj HealthCare | Jagsonpal Pharmaceuticals vs Wonder Fibromats | Jagsonpal Pharmaceuticals vs TIL | Jagsonpal Pharmaceuticals vs GPT Healthcare | |||
Share Price HistoryJAGSNPHARM FinancialsTomorrow TargetYearly TargetsDividend HistoryNo BonusNo Split
Show Table of Contents
Table of Contents
Jagsonpal Pharmaceuticals Recent Performance
Over the past 422 trading days, the value of Jagsonpal Pharmaceuticals's stock has lost ₹138.05 (-35.29%). On 07 Nov 2023, one share was worth ₹391.15 and by 24 Jul 2025, the value dropped to ₹253.10. During this period it created a highest high of ₹820.10 and lowest low of ₹192.85.
Jagsonpal Pharmaceuticals Share Price Target - Tomorrow
| Level | Value | Analysis |
|---|---|---|
| Tomorrow Target 3 | 274.8 (+8.57%) | Price Action: Jul 2025 High |
| Tomorrow Target 2 | 270 (+6.67%) | Price Action: 24 Jul 2025 High |
| Tomorrow Target 1 | 267 (+5.49%) | Price Action: Apr 2025 High |
| Current Price | 253.10 | Jagsonpal Pharmaceuticals's share price as of 24 Jul 2025 |
| Stop Loss 1 | 241.72 (-4.5%) | Price Action: 14 Jul 2025 Low |
| Stop Loss 2 | 239 (-5.58%) | Price Action: 10 Jun 2025 High |
| Stop Loss 3 | 236.4 (-6.6%) | Price Action: 13 Jun 2025 High |
Summary
24 Jul 2025: Jagsonpal Pharmaceuticals finished the day at ₹253.10, losing ₹-16.66 (-6.18%) in 1 day.
Our analysis for tomorrow predicts a potential movement of -6.60% to 8.57% with:
- Target prices: ₹267 to ₹274.8
- Support levels: ₹241.72 to ₹236.4
- Recent high: ₹270.00
- Recent low: ₹251.10
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Jagsonpal Pharmaceuticals Share Price Target - Next Week
| Level | Value | Analysis |
|---|---|---|
| Next Week Target 3 | 270 (+6.67%) | Price Action: 24 Jul 2025 High |
| Next Week Target 2 | 267 (+5.49%) | Price Action: Apr 2025 High |
| Next Week Target 1 | 260.85 (+3.06%) | Fibonacci Extension Level 23.60% |
| Current Price | 253.10 | Jagsonpal Pharmaceuticals's share price as of 24 Jul 2025 |
| Stop Loss 1 | 250 (-1.23%) | Price Action: 17 Jul 2025 Low |
| Stop Loss 2 | 245 (-3.21%) | Price Action: 02 May 2025 High |
| Stop Loss 3 | 242.44 (-4.22%) | Fibonacci Retracement Level 98.60% |
Weekly Target Summary
For next week, our analysis suggests a potential movement range of -4.21% to 6.68% with:
- Upper targets: ₹260.85 to ₹270
- Support levels: ₹250 to ₹242.44
Jagsonpal Pharmaceuticals Share Price Target - Next Month
| Level | Value | Analysis |
|---|---|---|
| Next Month Target 3 | 277.87 (+9.77%) | Technical Indicator: MA150 |
| Next Month Target 2 | 274.8 (+8.57%) | Fibonacci Extension Level 100.00% |
| Next Month Target 1 | 270 (+6.67%) | Price Action: 24 Jul 2025 High |
| Current Price | 253.10 | Jagsonpal Pharmaceuticals's share price as of 24 Jul 2025 |
| Stop Loss 1 | 248.88 (-1.67%) | Price Action: 06 May 2025 High |
| Stop Loss 2 | 245 (-3.21%) | Price Action: 02 May 2025 High |
| Stop Loss 3 | 241.98 (-4.4%) | Price Action: 22 Jul 2025 Low |
Monthly Target Summary
Looking ahead to next month, technical analysis indicates:
- Potential price movement: -4.39% to 9.79% with:
- Target range: ₹270 to ₹277.87
- Support levels: ₹248.88 to ₹241.98
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
